Translate to...

Pimavanserin reduced symptoms of dementia-related psychosis in phase 3 trial

A large-scale trial has found a treatment with pimavanserin substantially reduced psychotic symptoms and reduced risk of relapse of those symptoms compared to placebo in people with dementia, a condition for which no treatments are currently licensed.